atau cari berdasarkan hari
PT Kalbe Farma offers a collaborative program in Genexine Vaccine clinical trials to companies for their employees.
The BPOM has permitted the clinical trials for Ivermectin to test its potency as COVID-19 treatment.
The latest research by Sinovac vaccine producer in China says that a third shot is advised.
There is no longer any need for the government to be responsible for research into the Nusantara vaccine being promoted by former minister Terawan.
A number of national figures declared their supports toward Indonesian Food and Drug Monitoring Agency (BPOM).
BPOM Head Penny Lukito said the mass production of homegrown COVID-19 vaccine dubbed the Merah Putih vaccine was hoped to commence in early 2022.
BPOM Head Penny Lukito said the agency's assessment of the Nusantara Vaccine had complied with the applicable standards.
The Food and Drug Monitoring Agency (BPOM) said the interim data on the phase 2 clinical trial of the Nusantara vaccine was not sufficient.
Epidemiologist Dicky Budiman urges the government to not let the Nusantara vaccine to go on to its second clinical trial.
The Nusantara vaccine has yet to fulfill good clinical practices, proof of concept, laboratory practice, and manufacturing set by the BPOM.
Sinovac COVID-19 vaccine appears to be safe and able to trigger immune responses among children
Sinovac vaccine research team responds to news about 95 volunteers of clinical test allegedly exposed to Covid-19 during test periods.
The number of volunteers in the Sinovac vaccine clinical trial who tested positive for Covid-19 increased to 95 from previously 25 in mid-January.
BPOM will meet with the team of researchers behind Terawan Agus Putranto's 'Nusantara Vaccine' to conduct a clinical review.
The Padjadjaran University (Unpad) research team announces that it will be conducting clinical trials for the Anhui candidate vaccine.
The Eijkman Institute of Molecular Biology has the swiftest progress in developing the home grown 'Merah Putih vaccine' for Covid-19.
A coronavirus vaccine developed by China's Sinovac Biotech was 78% effective in a late-stage Brazilian trial and prevented severe COVID-19 cases.
The Sinovac vaccine clinical trial research team in Bandung is set to report the result of the immunization tests conducted in the past three months.
The COVID-19 vaccine clinical trial team planned to submit an interim report of the phase-3 trials of the vaccine candidates at the end of January.
Sinovac Biotech's Covid-19 candidate vaccine clinical trial will be evaluated by the BPOM.